Medical device company NxThera has raised a second round of series B funding from a combination of corporates and venture capital investors.

As part of a series of interviews with leading innovation and venture developers, Andrew Gaule, founder of the Corporate Venturing Network, talks to Graeme Martin (pictured), president of Takeda Ventures.

Non-profit research partnership the Structural Genomics Consortium adds Pfizer and Eli Lilly to its consortium as it closes a funding round worth nearly $50m.

The new investment will help fund the clinical development of MSI's formulations of s-adenosyl methionine (SAMe) to clinical proof of concept for the treatment of depression.